关键词

Thalidomide; clinical applications; mechanisms of action; combination therapy; targeted approaches; safety concerns; future persp

全文

PDF

参考

[1]Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
List A, Dewald G, Bennett J, et al.
[2] Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465.
[3] Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med.
1999;341(21):1565-1571.
[4] Chen C, Morgan GJ, Lista F, et al. Safety and efficacy of thalidomide in patients with transfusion-dependent anemia due to
myelodysplastic syndromes: results of a phase II study. Br J Haematol. 2006;134(2):154-159.
[5] Verma A, List A. Lenalidomide therapy in myelodysplastic syndromes: an update. Semin Hematol. 2012;49(3):256-265.
[6] Hasle H. Myelodysplastic syndrome in children. Curr Opin Pediatr. 2016;28(1):10-16.
[7] Yoshida N. Myelodysplastic syndrome in pediatric patients. Int J Hematol. 2018;107(5):512-517.
[8] Wei AH, Thanarajasingam G, Lad DP, et al. A phase II study of thalidomide therapy in myelodysplastic syndromes following stem cell
transplantation. Am J Hematol. 2006;81(3):162-167.
[9] Imamura T, Yokoyama H, Ohyashiki K. Efficacy of lenalidomide in patients with myelodysplastic syndrome with del(5q): a meta-analysis
of clinical studies. Leuk Res. 2009;33(6):837-842.